1. A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy
ClinicalTrials.gov Identifier: NCT01168973
Purpose: The purpose of this study is to compare overall survival in patients with Stage IV non-small cell lung cancer.
AB
Edmonton
NB
Moncton
QC
Sainte-Foy
2. Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
This study is ongoing, but not recruiting participants
ClinicalTrials.gov Identifier: NCT00409188
The purpose of this study is to determine whether the cancer vaccine Stimuvax in addition to best supportive care is effective in prolonging the lives of patients with unresectable stage III non-small cell lung cancer, compared to best supportive care alone.
AB
Tom Baker Cancer Center, Calgary
Cross Cancer Institute, Edmonton
BC
Fraser Valley Cancer Center, Surrey
BCCA Cancer Center, Vancouver Island
BCCA Cancer Center, Vancouver
MB
Cancer Care Manitoba, Winnipeg
NS
Capital District Health Authority, Halifax
Cape Breton District Health Authority Cancer Care, Sydney
ON
Juravinski Cancer Center, Hamilton
Niagara Health System, Saint Catherine’s
Thunder Bay Regional Health Center, Thunder Bay
Princess Margaret Hospital, Toronto
Mount Sinai Hospital, Toronto
Winsor Regional Cancer Center, Windsor
QC
Jewish General Hospital, Montreal
Hopital Notre Dame, Montreal
Hopital Laval, Sainte-Foy
3. MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
ClinicalTrials.gov Identifier: NCT01068587
RATIONALE: MET/VEGFR2 inhibitor GSK1363089 and erlotinib hydrochloride may stop the growth of tumour cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumour
ON
Princess Margaret Hospital, Toronto
Ottawa Regional Cancer Center, Ottawa
Juravinski Cancer Center, Hamilton
BC
BCCA, Vancouver Center
4. Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin
ClinicalTrials.gov Identifier: NCT01285609
Purpose: The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin
ON
Sudbury
QC
Montreal
5. An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
ClinicalTrials.gov Identifier: NCT00932893
Purpose: This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
AB
Calgary
Edmonton
QC
Montreal
ON
Ottawa
Oshawa
NB
Moncton
6. An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
ClinicalTrials.gov Identifier: NCT00932451
Purpose: This is a Phase 2 trial that will evaluate the safety and efficacy of PF-02341066 in patients with advanced non-small cell lung cancer with a specific gene profile involving the ALK gene. This trial will also allow patients from a Phase 3 trial who received standard of care chemotherapy (Study A8081007) to receive PF-02341066
AB
Edmonton
Calgary
QC
Montreal
ON
Ottawa
Oshawa
NB
Moncton
7. Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
This study is ongoing, but not recruiting participants
ClinicalTrials.gov Identifier: NCT00824408
The trial objective will be to evaluate whether BI 6727 monotherapy or in combination with pemetrexed may be effective in the treatment of advanced or metastatic NSCLC in patients who relapsed after or failed first-line platinum based therapy.
AB
Edmonton
ON
Hamilton
Kitchener
Ottawa
Toronto
Oshawa
QC
Montreal
BC
Surrey
Kelowna
Vancouver
8. A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Patients With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
ClinicalTrials.gov Identifier: NCT01456325
This randomized, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with Tarceva (erlotinib) in patients with incurable non-small cell lung cancer identified to be Met diagnostic-positive. Patients will be randomized to receive either onartuzumab (MetMAb) or placebo in combination with Tarceva. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
ON
Toronto
Sault Ste Marie
QC
Montreal
NB
Saint John
9. NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
ClinicalTrials.gov Identifier: NCT01098266
The main objective of the trial is to document the efficacy of NGR-hTNF administered at low dose weekly in advanced Malignant Pleural Mesothelioma patients previously treated with a pemetrexed-based chemotherapy regimen.
AB
Cross Cancer Institute, Edmonton